Your browser doesn't support javascript.
loading
Management of prolactinomas in Brazil: an electronic survey.
Vilar, Lucio; Naves, Luciana Ansaneli; Casulari, Luiz Augusto; Azevedo, Monalisa Ferreira; Albuquerque, José Luciano; Serfaty, Fabiano Marcel; Pinho Barbosa, Flavia R; de Oliveira, Antonio Ribeiro; Montenegro, Renan Magalhães; Montenegro, Renan Magalhães; Ramos, Alberto José Santos; Dos Santos Faria, Manuel; Musolino, Nina Rosa C; Gadelha, Monica R; Boguszewski, Cesar Luiz; Bronstein, Marcello D.
Afiliação
  • Vilar L; Division of Endocrinology, Hospital das Clinicas, Pernambuco Federal University, Rua Clovis Silveira Barros, 84/1202, Boa Vista, Recife, PE, CEP 50.050-270, Brazil. lvilar@gmail.com
Pituitary ; 13(3): 199-206, 2010 Sep.
Article em En | MEDLINE | ID: mdl-20107911
Dopamine agonists are the treatment of choice for prolactinomas. However, there are still controversies concerning dose, treatment duration and criteria for drug withdrawal in different clinical situations. The aim of this study was to assess diagnostic and therapeutic approaches to prolactinomas among members of the Brazilian Society of Endocrinology and Metabolism (SBEM). SBEM members answered a questionnaire sent by e-mail that included 18 questions related to controversial issues about the management of prolactinomas. Among SBEM members, 721 (approximately 24% of total) answered the questionnaire. Concerning the diagnosis, 38% of the respondents stated that prolactin levels < 100 ng/ml would exclude the presence of a prolactinoma. Most of them favored the screening for macroprolactin in asymptomatic individuals instead of a routine screening (74% vs. 26%). Regarding the treatment, 70% of the respondents chose cabergoline as the drug of choice to treat macroprolactinomas whereas similar proportions advised cabergoline or bromocriptine as the best treatment for microprolactinomas (52% vs. 48%). Only 20% and 34% of respondents favored treatment withdrawal 2-3 years after prolactin normalization in patients with macroprolactinomas and microprolactinomas, respectively. In case of pregnancy, only 58 and 70% of respondents advocated discontinuation of treatment with dopamine agonists in patients with macroprolactinomas and microprolactinomas, respectively. Finally, only 36% would allow breast-feeding without restriction, 44% would restrict it to patients with microprolactinomas and 20% would not recommend it for women with prolactinomas There are several points of disagreement among SBEM members regarding the management of prolactinomas.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactinoma Limite: Female / Humans / Pregnancy País/Região como assunto: America do sul / Brasil Idioma: En Revista: Pituitary Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactinoma Limite: Female / Humans / Pregnancy País/Região como assunto: America do sul / Brasil Idioma: En Revista: Pituitary Assunto da revista: ENDOCRINOLOGIA Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos